MAPT and Alzheimer disease: The dysfunction of cerebral glucose metabolism in early stages of AD is testified [23], and the molecular markers of insulin resistance is found to colocalize with tau inclusions in AD brain [24], indicating that the insulin-involved pathway may be a vital element to the AD pathophysiological cascade [25].